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The present report demonstrates the presence in cultured rat aortic smooth muscle cells of a natriuretic factor receptor subtype with a specificity 
typical of the ANF-R~c (B-clone) receptor subtype. To prove the existence of this receptor subtype in this cell line we show that pCNP.(82-103) 
is the most potent activator of the intrinsic guanylate cyclase activity, and that [~"Sl]pCNP-(82-103) hinds to a specific r~ptor  subtype which is 
insensitive to the ANF-R. 2 specific ligand, C-ANF. The investigation f its binding characteristi~ show tho rank potency order of the natriareti¢ 
factors in competing for pCNP binding to be pCNP > pBNP > rANF. Furthermore it wa~ possible to eovalently photolab¢l this receptor subtype 
with underivatized ]~2SllpCNP and show that it is composed of a single nubunit of 130 kDa with very high specificity for pCNP. 
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1. INTRODUCTION 
Signal transduction ofnatriuretic factors involves the 
binding to specific high affinity membrane receptors. 
These atrial natriuretic factors (ANF) receptors are di- 
vided into two main classes: ANF-R~ and ANF-R: re- 
ceptors. The first class, ANF-R~, which possesses a
guanylate cyclnse catalytic activity, is subdivided into 
several subtypes with distinct pharmacological specific- 
ity for the different natriuretic factors [1,2]. Two of 
these have been cloned, the ANF-R ~A subtype (A-clone) 
and the ANF-R~c subtype (B-clone). The ANF-R~A 
subtype is mostly specific for both ANF and brain 
natriuretic peptide (BNP) [3,4] and is found at high 
concentration in many target organs of these natriuretic 
peptides [5]. The ANF-R~c subtype is mainly specific for 
C-type natriuretic peptide (CNP) [2] and its distribution 
is limited to tissues of neuronal origin [5]. The ANF-Rm 
subtype, which has not yet been cloned, displays higher 
affinity for ANF than for BNP [1] and does not recog- 
nize CNP. The ANF-Rz receptor class, which has been 
cloned, does not discriminate between these peptides [6], 
is widely distributed [5] and recognizes biologically in- 
active ANF derivatives e.g. [CysZt~]rANF-(102-116)x- 
NH2 (C-ANF). Until recently there was no direct evi- 
dence showing the existence of the ANF-R~c receptor 
subtype specific for CNP binding. A report showing 
that CNP was more potent than ANF in increasing 
cGMP production in cultured rat aortic smooth muscle 
cells (RASM) [7] indicated that this subtype might be 
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present in a cultured non-neuronal cell type. Although 
it is known from studies using recombinant receptor 
that the ANF-R~c is specific for CNP, no reports have 
shown a complete characterization f this receptor sub- 
type in target organs for natriuretic factors. In order to 
prove the pharmacological relevance of the ANF-RIc 
subtype, it is of prime importance to identify and char- 
acterize this receptor subtype in such target organs. Our 
results how a complete characterization f the binding 
and enzymatic properties of this receptor subtype in 
cultured rat aortic smooth muscle cells. 
2. MATERIALS AND METHODS 
2.1. Cell culture 
Rat aortic smooth muscle cells (RASM) were a gift from Dr. P. 
Hornet of the Research Center of the Hotel-Dieu Hospital of Mon- 
treal. They were grown in Dulbeeco's modified Eagle medium supple- 
mented with 5% calf serum and 100 U of penicillin--streptomycin 
(Gib¢o, Canada). 
2,2. Cyclic GMP determination 
Upon reaching confluence oell monolayers were stimulated in Dul- 
beceo's modified Eagle medium in the presence of 0.5 mM IBMX as 
previously descrilx-,d [6] and extracellalar cyclic (iMP production was 
measured by radioimmunoa~say [6]. 
2.3. Preparation of membranes 
Confluent RASM cells were washed 3times with ice-cold saline and 
scrapped from their plates. After a 10 min centrifusation at250 × g 
the cell pellet was homogenized in 10 vols. of buffer A (50 mM Tris- 
HCI, pH 7.4, 250 mM sucrose, 5mM EDTA, 100 mM HoOt, 10 -7 M 
aprotinin, 10-* M leupeptin, and 10-: M pepstatin A) with a polytran 
homogenizer. The homogenate was centrifuged at600 ~ g for 10 rain, 
the pellet discarded, and the su~rnatant was then centrifuged at 
t00,000 x g Ibr 30 rain. After a ~¢ond centrifugation the resulting 
pellet was resusImnded in buffer B (50 mM Tris-HCl, 0.1 mM EDTA, 
250 mM sucrose, 1mM MgCi2, pH 7.4). The membranes were frozen 
in liquid nitrogen and stored at -70"C until used. 
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2,4. Ic~)inatiotz procedtcre 
Tyr°-pCNP-(82-103) (Peninsula Lab,, CA), and saceitfimld2A-c:/clie 
GMP.tyrosyl-meth)'l-ester (Sigma Chemicals, Me) were iodinated 
with the enz~,mobead techni0ue (Bio-Rad) according to the directives 
of the manufacturer. The rnono-iodinated product was purified on 
RP-HPLC as described [8], 
2.5. Receptor binding assay 
The binding studies were carried out essentially as previously de- 
scribed [9] in the presence or absence of C-ANF (0.1 ,aM) at 4°C 
overnight, 
2.6. Photoaffinity labeling protocol 
Membranes from RASM cells were photoaflinity labeled as previ- 
ously reported [10]. Briefly, 80/~g/ml of membrane proteins were 
incubated in the dark at 10*C for 18 h with 30 pM of [t"SI]Tyr°-peNP 
in the presence or absen~ of unlabeled peptides in l ml of buffer C 
(50 mM Tris-HCl, pH 7.4, 0.1 mM EDTA, 0,5% BSA, and 5 mM 
MnClz). After the incubation period the membranes were photolys~ 
for 20 min. Following irradiation the membrane proteins were pelleted 
at 12,000 x g for 15 rain, washed once in buffer C without BSA. 
resuspended in 100#1 of sample buflk:r (62 mM Tris-HCl, pH 6,8, 2% 
SDS, 10% glycerol, 0,001% Bromophcnol blue, and 5% 2-mereap- 
tocthanol) and heated at 100*C for 3 rain prior to ¢loctrophoresis, 
Z% SDS.polyacrylamide g l eteetrophoresis 
Proteins were analyzed by electrophoresis on a 7.5% acrylamide gel 
according to the method of Laemmli [1 l]. An amount of 80 pg :ff 
proteins was loaded onto each lane. Autoradiograms arc shown after 
8-10 days caposurc of the fixed-dried gels at -70°C. 
2.8. Data analysis 
Dose-response curves for cyclic GMP production were analyzed 
with the four-parameter logistic equation [t2]. Competition binding 
curves were analyzed with a non.linear least-squares curve fitting 
program to obtain estimates ofthe binding equilibrium constant of the 
different peptides [13], 
3. RESULTS 
Characterization f the natriumtic peptide pharma- 
cological profile in rat aortic smooth muscle cells shows 
that pCNP is the most potent stimulator of the intrinsic 
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Fig. 2. Competition binding curves of different natriuretie factors for 
the binding of [:Sl]pCNP-(82-103) to RASM cell membranes in the 
absence of C-ANF. 
in terms of ED~0 and maximal effect (Fig. 1). pCNP 
stimulates the enzyme up to 450-fold with an EDso of 
5 nM, while rANF and pBNP were less potent with 
EDs0'S of 9.5 and 27.6 nM respectively. When the en- 
zyme activity was assayed irectly on RASM cell mem- 
branes pCNP was still the most  potent activator of 
guanylate cyelase activity (data not shown). In addition 
we have observed that the ANF-R2 specific derivative, 
C-ANF, did not antagonize the stimulatory effect of 
either pCNP, ANF or BNP in RASM cells (data not 
shown). 
The binding specificity or the natriuretic peptide re- 
ceptor present on RASM cell membranes was also in- 
guanylate cyclase activity of the receptor protein, both ~' 0.2 
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Fig. 1. Representative dose-response curve of pCNP. pBNP, and 
rANF on the production of cyclic GMP by rat aortic smooth muscle 
cells in culture. The cells were challenged with the different peptides 
for 3 h at 37"C and ¢xtracellular cyclic GMP was assayed as described 
[61. 
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Fig. 3. Competition binding curves of different natriuretic factors for 
the binding of [t-'SIlpCNP-(82-103) to RASM c¢1t membranes in the 
presence of C-ANF (0.1/zM). 
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vestigated. Fig. 2 illustrates that [l~51]Tyr°-pCNP-(82 - 
103) labels a population of receptor sites with a specific- 
ity indicative of a predominant ANF-R2 class and a 
total density of sites of 490 fmol/mg of protein. The 
majority of receptors present on RASM cell membranes 
do not discriminate between the different natriuretic 
peptides as they recognize all the natriuretic peptides 
with similar affinities. Fig, 2 also shows that C-ANF 
potently competed for 90% of [ta~I]pCNP-(82-103) spe- 
cific binding sites. 
In order to investigate he C-ANF ir~zensitive sites we 
have characterized their pharmacological binding pro- 
file in the presence of a saturating concentration of 
C-ANF in order to block the ANF-R~ sites. Fig. 3 
shows that the rank potency order for this receptor 
subtype is: pCNP > pBNP > rANF, with a selectivity 
ratio for pCNP over rANF of $0-fold and over pBNP 
of 13-fold, and a density of 60 fmol/mg of protein. This 
CNP-specific receptor was photoaffinity labeled with 
[t~-~l]Tyr°-pCNP-(82-103) in order to determine its mo- 
lecular size. Fig. 4 shows the specific photolabeling of
2 protein bands: a minor band at 130 kDa, correspond- 
ing to the pCNP-specific ANF-R~c subtype, and a 
major band at 64 kDa, corresponding to the ANF-R2 
subtype. The selectivity of the receptor band was as- 
sessed by competition of [12SI]Tyr°-pCNP-(82-103) la- 
beling with increasing concentrations of unlab,zled 
pCNP or rANF in the presence of a saturating concen- 
tration of C-ANF. Fig. 5 clearly demonstrates that the 
130-kDa high molecular weight protein is specific for 
pCNP and has a lower affinity for rANF, and corre- 
sponds to the ANF-R]c subtype documented in Fig. 3. 
4. DISCUSSION 
The characterization of the binding profile of the 
ANF-R~c receptor subtype in RASM cells is the same 
as that obtained from the expressed receptor clones [2] 
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Fig. 4. Photoaffinity labelin~ of the ANF-R=c receptor sabqqm by 
[~:Sl]pCNP in RASM cell membrane in the presence or abscn¢~ of 
Ulflabeled pCNP. Membrane proteins were subjected to $DS-gcl elec- 
trophoresis on a 7.5% acrylamide gel. Molecular weight protain stan- 
dards (Da) are myosin (200,000), fl-galagto=ida~¢ (116,250), 
phosphorylase b (97,400). bovine serum albumin (66.200), ovalbumin 
(42,699). and carbonic anhydrase (31,000). 
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Fig. 5. Competition of the labelin B of the ANF-RIc by [ml]pCNP with increasing concentrations of unlabeled pCNP and rANF. 
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i.e. pCNP > pBNP > rANF, indicating that we have 
efl~etively identified the same ANF-R~c (B-clone) re- 
ceptor subtype that was previously revealed by guanyl- 
ate cyelase studies [7], Examination of the CNP binding 
characteristics of the major ANF  receptor population 
in RASM,  in the absence of C-ANF, reveals a profile 
that is typical of ANF-R2 receptors. But interestingly 
blockade by C-ANF of ANF-R~ sites discloses the 
ANF-R~c sites corresponding to about I0% of the total 
density of CNP-specifie binding sites and which was not 
documented in previous studies. In addition to these 
functional aspects of the ANF-Rtc receptor we have 
analyzed its protein structure after photoaffinity label- 
ing with [1251]pCNP. Like the ANF-RtA the ANF-RIc  
is a 130-kDa monomer. The sp~ificity of the photola- 
beled receptor protein was demonstrated bydirect com- 
petition of [~-'SI]pCNP-(82-103) binding with pCNP and 
rANF, showing that this receptor subtype was specific 
for pCNP and had very low affinity for rANF. 
These results contrast somewhat with previous re- 
ports which showed that pCNP could only label a 70- 
kDa protein band in cultured rat aortic smooth muscle 
cells, corresponding to the ANF-R2 receptor subtype 
[7]. It is possible that this 70-kDa band might have 
resulted from proteolytic cleavage of a higher molecular 
weight pl:otein band as previously reported [14]. In our 
study proteolytic attack of the ANF-R~c receptor sub- 
type was avoided by introducing protease inhibitors. 
The observation of a lower maximal stimulation of the 
enzymatic activity produced by rANF, in contrast o 
pBNP and pCNP, is still unclear. It is possible that this 
cell type expresses very low levels of ANF-RtA receptor 
subtype, which preferentially responds to rANF, there- 
fore explaining the lower levels of cGMP attained with 
rANF. Alternatively the fact that rANF does not show 
a higher potency, which would be consistent with its 
high affinity on the ANF-R~A receptor subtype, is possi- 
bly due to its phosphorylation by an ecto-cAMP-de- 
pendent protein kinase [15], which would be responsible 
for its lower potency consistent with its decreased 
vasorelaxant activity [16]: however, the presence of such 
ectokinase in RASM cells remains to be proven. We 
could also suggest hat this difference in maximal 
cGMP production might be due to a lower efficacy of 
rANF on the ANF-R~c receptor subtype and that the 
lower potency of rANF is only the resultant potency of 
the peptide on a majority of ANF-R~c and a minority 
of ANF-R~A receptor subtypes in RASM cells. 
In summary we have identified and characterized the 
ANF-R~c (B-clone) receptor subtype in cultured rat 
aortic smooth muscle cells. We show that it is specific 
for pCNP and has a very low affinity for rANF, which 
shows a very low efficacy on the activation of this recep- 
tor subtype's enzymatic activity. This receptor subtype 
is present in small amounts and represents 10-15% of 
the total binding capacity for natriuretic peptides in this 
cell type, the rest being contributed by the ANF-R2 
subtype. 
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